Pharmaceutical

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.

Mar 16, 2024 - 00:00
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.
Read the original article

Tags:

Previous Article

Noramco launches North American pharma supply chain services provider

Next Article

Q&A: Increasing awareness around digital therapeutics key to realising full pote...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting

Opinion: Liquid biopsy for cancer recurrence creates a ...

Oct 30, 2023

STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors

STAT+: In response to criticism, FDA publishes new data...

Dec 15, 2023

STAT+: European companies outline opposition to proposed overhaul of pharma policy

STAT+: European companies outline opposition to propose...

Jun 22, 2023